Casein Kinase
Casein Kinases (CKs), a group of ubiquitous Ser/Thr kinases, regulate a wide range of cellular functions in eukaryotes, including phosphorylation of proteins that are substrates for degradation via the ubiquitin-proteasome system (UPS). Two casein kinases, casein kinase-1 (CK-1) and casein kinase-2 (CK-2), have been characterized from many sources.
CK1 kinases exist in at least seven isoforms (α, β, γ1-3, δ, and ɛ) in mammals and CK1 kinases phosphorylate various substrates to play vital roles in diverse physiological processes such as DNA repair, cell cycle progression, cytokinesis, differentiation, and apoptosis. Casein kinase 2 (CK2) is a highly pleiotropic serine-threonine kinase, which catalyzed phosphorylation of more than 300 proteins that are implicated in regulation of many cellular functions, such as signal transduction, transcriptional control, apoptosis, and the cell cycle.
Casein Kinase Isoform Specific Products
All Product Categories
-
Casein Kinase Inhibitors
(201)
View all products
-
Casein Kinase Antagonists
(2)
View all products
-
Casein Kinase Activator
(1)
View all products
-
Casein Kinase Chemical
(1)
View all products
-
Casein Kinase Degraders
(23)
View all products
-
Casein Kinase Substrate
(1)
View all products
-
Casein Kinase Ligand
(1)
View all products
-
Casein Kinase Related Products (247)
Related Products (247)
-
Antibodies (5)
-
Casein Kinase Isoform Comparison
-
CK1δ-IN-7
0 ImagesCat. No.: HY-169556CAS No.: 882220-11-3CK1δ-IN-7 (Compound 488) is the inhibitor for casein kinase 1δ (CK1δ).
-
TAK-715 (Standard)
0 ImagesCat. No.: HY-10456RCAS No.: 303162-79-0TAK-715 (Standard) is the analytical standard of TAK-715 (HY-10456). This product is intended for research and analytical applications. TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model.
-
CZP-IN-1
0 ImagesCat. No.: HY-170782CZP-IN-1 (compound SH-1) is an inhibitor targeting the pathogen Trypanosoma cruzi cruzipain (CZP) and does not inhibit cathepsin L (IC50=28 nM). CZP-IN-1 can be used for the research of Chagas disease.
-
PLK1-IN-17
0 ImagesCat. No.: HY-184863CAS No.: 1034617-66-7PLK1-IN-17 is a potent PLK1 inhibitor with an IC50 of 2 nM. PLK1-IN-17 shows high selectivity for PLK2 and CDK2/A, moderate selectivity for PLK3, only weak activity against CK2, FLT3 and NEK6, and no activity against PDGFR, ALK and another 37 kinases. PLK1-IN-17 inhibits the proliferation of ovarian cancer cells and can be used in ovarian cancer-related research.
-
CK1δ-IN-8
0 ImagesCat. No.: HY-W840382CAS No.: 438018-70-3CK1δ-IN-8 (Compound 429) is a CK1δ inhibitor that can be used in Alzheimer's disease research.
-
AMG-548 dihydrochloride (Standard)
0 ImagesCat. No.: HY-108642BRCAS No.: 2518299-32-4AMG-548 dihydrochloride (Standard) is the analytical standard of AMG-548 (dihydrochloride) (HY-108642B). This product is intended for research and analytical applications. AMG-548 dihydrochloride, an orally active and selective p38α inhibitor (Ki=0.5 nM), shows slightly selective over p38β (Ki=36 nM) and >1000 fold selective against p38γ and p38δ. AMG-548 dihydrochloride is also extremely potent in the inhibition of whole blood LPS stimulated TNFα (IC50=3 nM). AMG-548 dihydrochloride inhibits Wnt signaling by directly inhibiting Casein Kinase 1 isoforms δ and ε.
-
D4476 (Standard)
0 ImagesCat. No.: HY-10324RCAS No.: 301836-43-1Synonyms: Casein Kinase I Inhibitor (Standard)
-
Umbralisib (Standard)
0 ImagesSynonyms: TGR-1202 (Standard); RP5264 (Standard)Umbralisib (Standard) is the analytical standard of Umbralisib. This product is intended for research and analytical applications. Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach.
-
CIGB-300
0 ImagesCat. No.: HY-P4056CAS No.: 1072877-99-6Synonyms: P15-TatCIGB-300 (P15-Tat) is an anti-casein kinase 2 (CK2) peptide that exhibits anticancer properties by interfering with the phosphorylation of protein kinase CK2. CIGB-300 induces apoptosis in multiple tumor cell lines and can be used in cancer research.
-
Ac-ESMD-CHO
0 ImagesCat. No.: HY-P3234CAS No.: 191338-87-1
-
LY294002 hydrochloride (Standard)
0 ImagesLY294002 (hydrochloride) (Standard) is the analytical standard of LY294002 (hydrochloride). This product is intended for research and analytical applications. LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research.
-
PI-828 (Standard)
0 ImagesCat. No.: HY-108606RCAS No.: 942289-87-4
-
Casein kinase 1δ-IN-30
0 ImagesCat. No.: HY-169677CAS No.: 849012-74-4Casein kinase 1δ-IN-30 (Compound 581) is a Casein kinase 1δ (CK1δ) inhibitor. Casein kinase 1δ-IN-30 can be used in the research of neurodegenerative diseases.
-
CK1δ-IN-5
0 ImagesCat. No.: HY-169713CAS No.: 956753-89-2CK1δ-IN-5 (Compound 24) is a Casein kinase 1δ (CK1δ) inhibitor. CK1δ-IN-5 can be used in the research of neurodegenerative diseases.
-
Lenalidomide-d4
0 ImagesCat. No.: HY-A0003S3CAS No.: 1130061-52-7Synonyms: CC-5013-d4Lenalidomide-d4 (CC-5013-d4) is the d4-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
-
TBCA (Standard)
0 ImagesCat. No.: HY-110052RCAS No.: 934358-00-6TBCA (Standard) is the analytical standard of TBCA (HY-110052). This product is intended for research and analytical applications. TBCA is a highly selective CK2 (casein Kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other Kinases.
-
Casein Kinase II Inhibitor IV (Standard)
0 ImagesCat. No.: HY-111378RCAS No.: 863598-09-8Casein Kinase II Inhibitor IV (Standard) is the analytical standard of Casein Kinase II Inhibitor IV (HY-111378). This product is intended for research and analytical applications. Casein Kinase II Inhibitor IV is a potent, ATP-competitive of casein Kinase II inhibitor with an IC50 of 9 nM. Casein Kinase II Inhibitor IV ia also a human keratinocytes (NHEK) differentiation inducer.
-
CK1-IN-1 (Standard)
0 ImagesCat. No.: HY-111820RCAS No.: 1784751-20-7CK1-IN-1 (Standard) is the analytical standard of CK1-IN-1 (HY-111820). This product is intended for research and analytical applications. CK1-IN-1 (Compound 1c) is a casein Kinase 1 (CK1) inhibitor with IC50 values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC50 of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis.
-
Silmitasertib sodium salt (Standard)
0 ImagesSynonyms: CX-4945 sodium salt (Standard)Silmitasertib (sodium salt) (Standard) is the analytical standard of Silmitasertib (sodium salt). This product is intended for research and analytical applications. Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
